Pearl Therapeutics has reported positive top-line results from a randomized, double-blind, phase IIb, dose-ranging study of glycopyrrolate, a long-acting muscarinic agonist delivered twice a day via metered-dose inhaler in patients with moderate-to-severe COPD. Four doses of GP MDI were compared to placebo and Atrovent HFA Inhalation Aerosol, a short-acting muscarinic antagonist given four times a day. All doses of GP MDI tested produced statistically significant improvements in lung function compared to placebo. Further, doses of PT001 were identified that were non-inferior to Atrovent HFA. PT001 was well tolerated and no safety concerns were identified.